Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
The issuances were directed to new U.S. sector specialist investors. One of the issuances of warrants is subject to approval by an extraordinary general meeting.
Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi, Elias Kröger and Johannes Ekbom (Capital Markets and Public M&A).
